664 related articles for article (PubMed ID: 36699466)
21. Comprehensive Analysis and Reinforcement Learning of Hypoxic Genes Based on Four Machine Learning Algorithms for Estimating the Immune Landscape, Clinical Outcomes, and Therapeutic Implications in Patients With Lung Adenocarcinoma.
Sun Z; Zeng Y; Yuan T; Chen X; Wang H; Ma X
Front Immunol; 2022; 13():906889. PubMed ID: 35757722
[TBL] [Abstract][Full Text] [Related]
22. A bioinformatics-based immune-related prognostic index for lung adenocarcinoma that predicts patient response to immunotherapy and common treatments.
Wang C; Lu T; Xu R; Chang X; Luo S; Peng B; Wang J; Yao L; Wang K; Shen Z; Zhao J; Zhang L
J Thorac Dis; 2022 Jun; 14(6):2131-2146. PubMed ID: 35813746
[TBL] [Abstract][Full Text] [Related]
23. Histone acetylation modification regulator-mediated tumor microenvironment infiltration characteristics and prognostic model of lung adenocarcinoma patients.
Wang W; Shen Y; Zhang P; Liu L; Sha X; Li H; Wang S; Zhang H; Zhou Y; Shi J
J Thorac Dis; 2022 Oct; 14(10):3886-3902. PubMed ID: 36389327
[TBL] [Abstract][Full Text] [Related]
24. Identification and validation of a novel prognostic model of inflammation-related gene signature of lung adenocarcinoma.
Luo D; Feng W; Ma Y; Jiang Z
Sci Rep; 2022 Aug; 12(1):14729. PubMed ID: 36042374
[TBL] [Abstract][Full Text] [Related]
25. Big data analysis identified a telomere-related signature predicting the prognosis and drug sensitivity in lung adenocarcinoma.
Zhang W
Medicine (Baltimore); 2023 Nov; 102(46):e35526. PubMed ID: 37986388
[TBL] [Abstract][Full Text] [Related]
26. A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma.
Wu J; Li L; Zhang H; Zhao Y; Zhang H; Wu S; Xu B
Oncogene; 2021 Jul; 40(26):4413-4424. PubMed ID: 34108619
[TBL] [Abstract][Full Text] [Related]
27. CD1B is a Potential Prognostic Biomarker Associated with Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Adenocarcinoma.
Li Z; Feng Y; Li P; Wang S; Liu X; Xia S
Int J Gen Med; 2022; 15():3809-3826. PubMed ID: 35418778
[TBL] [Abstract][Full Text] [Related]
28. Vesicle-mediated transport-related genes are prognostic predictors and are associated with tumor immunity in lung adenocarcinoma.
Qian C; Jiang Z; Zhou T; Wu T; Zhang Y; Huang J; Ouyang J; Dong Z; Wu G; Cao J
Front Immunol; 2022; 13():1034992. PubMed ID: 36524130
[TBL] [Abstract][Full Text] [Related]
29. Integrative transcriptional characterization of cell cycle checkpoint genes promotes clinical management and precision medicine in bladder carcinoma.
Shi WW; Guan JZ; Long YP; Song Q; Xiong Q; Qin BY; Ma ZQ; Hu Y; Yang B
Front Oncol; 2022; 12():915662. PubMed ID: 36033441
[TBL] [Abstract][Full Text] [Related]
30. Integrative learning in developing an immunologic lncRNA signature as a consensus risk-stratification tool for lung adenocarcinoma.
Chen Z; Liu Y; Wan C; Huang W
J Thorac Dis; 2023 Apr; 15(4):1823-1837. PubMed ID: 37197549
[TBL] [Abstract][Full Text] [Related]
31. Development and Validation of a Machine Learning Prognostic Model of m5C Related immune Genes in Lung Adenocarcinoma.
Cao X; Ji Y; Li J; Liu Z; Chen C
Cancer Control; 2024; 31():10732748241237414. PubMed ID: 38537151
[TBL] [Abstract][Full Text] [Related]
32. Tumor microenvironment related novel signature predict lung adenocarcinoma survival.
Chen J; Zhou R
PeerJ; 2021; 9():e10628. PubMed ID: 33520448
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
[TBL] [Abstract][Full Text] [Related]
34. Evaluating the Prognostic and Therapeutic Potentials of the Proteasome 26S Subunit, ATPase (
Ullah MA; Islam NN; Moin AT; Park SH; Kim B
Front Genet; 2022; 13():935286. PubMed ID: 35938038
[TBL] [Abstract][Full Text] [Related]
35. Development and validation of a DNA damage repair-related gene-based prediction model for the prognosis of lung adenocarcinoma.
Qin C; Fan X; Sai X; Yin B; Zhou S; Addeo A; Bian T; Yu H
J Thorac Dis; 2023 Dec; 15(12):6928-6945. PubMed ID: 38249902
[TBL] [Abstract][Full Text] [Related]
36. A more novel and powerful prognostic gene signature of lung adenocarcinoma determined from the immune cell infiltration landscape.
Ma C; Li F; He Z; Zhao S
Front Surg; 2022; 9():1015263. PubMed ID: 36311939
[TBL] [Abstract][Full Text] [Related]
37. A New Prognostic Indicator of Immune Microenvironment and Therapeutic Response in Lung Adenocarcinoma Based on Peroxisome-Related Genes.
Xiong Z; Zhang L; Fan W
J Immunol Res; 2022; 2022():6084589. PubMed ID: 35935579
[TBL] [Abstract][Full Text] [Related]
38. A novel pyroptosis related genes signature for predicting prognosis and estimating tumor immune microenvironment in lung adenocarcinoma.
Wu C; Zhao J; Wang X; Wang Y; Zhang W; Zhu G
Transl Cancer Res; 2022 Aug; 11(8):2647-2659. PubMed ID: 36093538
[TBL] [Abstract][Full Text] [Related]
39. Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis.
Ye Y; Jiang H; Wu Y; Wang G; Huang Y; Sun W; Zhang M
Front Mol Biosci; 2022; 9():1001225. PubMed ID: 36213111
[No Abstract] [Full Text] [Related]
40. Clinical Significance and Immunometabolism Landscapes of a Novel Recurrence-Associated Lipid Metabolism Signature In Early-Stage Lung Adenocarcinoma: A Comprehensive Analysis.
Zhu M; Zeng Q; Fan T; Lei Y; Wang F; Zheng S; Wang X; Zeng H; Tan F; Sun N; Xue Q; He J
Front Immunol; 2022; 13():783495. PubMed ID: 35222371
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]